California State Teachers Retirement System Sells 201,827 Shares of Pfizer Inc. $PFE

California State Teachers Retirement System lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,005,182 shares of the biopharmaceutical company’s stock after selling 201,827 shares during the period. California State Teachers Retirement System’s holdings in Pfizer were worth $252,866,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PFE. Evolution Wealth Management Inc. raised its holdings in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the 4th quarter worth approximately $26,000. YANKCOM Partnership purchased a new stake in Pfizer during the 4th quarter valued at $28,000. HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC lifted its holdings in shares of Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. Guggenheim cut their price objective on Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a report on Monday, July 13th. BMO Capital Markets dropped their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. JPMorgan Chase & Co. cut their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.25 on Wednesday. The company has a market capitalization of $143.88 billion, a P/E ratio of 19.27 and a beta of 0.35. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The firm’s 50 day simple moving average is $25.09 and its two-hundred day simple moving average is $26.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm earned $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts expect Pfizer to beat second-quarter earnings estimates, supported by favorable earnings expectations and improving revenue trends. The prospect of another earnings surprise may be encouraging investors ahead of the report. Pfizer Expected to Beat Earnings Estimates
• Positive Sentiment: Pfizer completed a Phase 1 study evaluating the tablet formulation of ibuzatrelvir, an antiviral candidate. While early-stage data do not establish commercial success, the update represents progress in Pfizer’s pipeline and could support longer-term growth expectations. Pfizer Fine Tunes Ibuzatrelvir Tablet
• Positive Sentiment: The FDA’s priority review of TALZENNA in combination with XTANDI for an earlier prostate-cancer setting could expand Pfizer’s oncology franchise. Investors may view the opportunity as a potential offset to declining legacy and COVID-related products. FDA Priority Review of TALZENNA
• Positive Sentiment: Several market commentaries highlighted Pfizer’s discounted valuation and argued that its patent-cliff concerns may already be reflected in the share price. This value-investing narrative likely contributed to buying interest. Pfizer Valuation and Patent Cliff Analysis

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.